New York: US biotech firm Moderna Inc on Monday said preliminary data from a continuing phase three study of its experimental COVID-19 vaccine showed it to be 94.5 percent effective.
“This is a pivotal moment in the development of our COVID-19 vaccine candidate,” said Moderna’s CEO Stephane Bancel in a statement. “This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease.”
“The NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against Covid-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5 per cent,” Moderna said in a statement.
The news follows on from last week’s announcement from US drug giant Pfizer that phase three trial results for the COVID-19 vaccine it is developing with Germany’s BioNTech showed it to be more than 90 percent effective.
The results of both trials place Moderna and Pfizer on track to seek authorisation from the US Food and Drug Administration in the coming weeks for emergency use of their vaccines.
Indian government is in dialogue with US biotech giant Moderna, regarding initial successful development of its Covid-19 vaccine candidate, which the drugmaker on Monday announced had achieved 94.5 per cent efficacy in phase 3 trials.